anaplastic oligodendroglioma

an·a·plas·tic ol·i·go·den·dro·gli·o·ma

an aggressive oligodendroglioma characterized by prominent nuclear pleomorphism, mitoses, and increased cellularity.
Mentioned in ?
References in periodicals archive ?
Andrew Brown, 27, was diagnosed with stage three anaplastic oligodendroglioma in September last year after suffering several "violent" seizures.
Approximately 60% of these tumors had additional features of nuclear atypia, increased mitotic rate, necrosis, and/or endothelial proliferation necessitating a diagnosis of anaplastic oligodendroglioma, WHO grade III.
anaplastic ependymoma, anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic meningioma).
Histopathological evidence revealed the nature of the cyst as grade 3, anaplastic oligodendroglioma, which is an extremely rare manifestation of this multi systemic disorder.
Survival estimates were significantly higher for females than for males in all histology groups with the exception of GBM and anaplastic oligodendroglioma, where survival rate differences by sex were not statistically significant.
Malignant gliomas include WHO grade III: anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma, and WHO grade IV: glioblastoma and gliosarcoma.
Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma.
As for the mandatory elements of a CNS tumor report summarized by Parisi et al, (8) these are all routinely included in a proper traditional diagnostic line and gross description; for example, "Brain, right frontal tumor, stereotactic biopsy: Anaplastic oligodendroglioma (WHO grade III) (see comment).
In 1998, Cairncross and colleagues (4) reported that loss of 1p (and combined loss of 1p and 19q) predicts a better response to procarbazine-lomustine-vincristine chemotherapy and a longer survival in patients with anaplastic oligodendroglioma.
Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.